Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma
The purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Inclusion Criteria:
Janssenmedinfo@its.jnj.com1-800-526-7736
Little Rock, Arkansas 72205, United States
Los Angeles, California 90048, United States
Aurora, Colorado 80045, United States
Miami, Florida 33136, United States
Miami, Florida 33176, United States
Honolulu, Hawaii 96826, United States
Chicago, Illinois 60611, United States
Evanston, Illinois 60201, United States
Indianapolis, Indiana 46237 8601, United States
Louisville, Kentucky 40202, United States
Farmington Hills, Michigan 48334, United States
Grand Rapids, Michigan 49503, United States
Minneapolis, Minnesota 55455, United States
Hackensack, New Jersey 07601, United States
New Brunswick, New Jersey 08901-1914, United States
Manhasset, New York 11030, United States
New York, New York 10029, United States
Winston-Salem, North Carolina 27157, United States
Columbus, Ohio 43210, United States
Oklahoma City, Oklahoma 73104, United States
Philadelphia, Pennsylvania 19104, United States
Pittsburgh, Pennsylvania 15323, United States
San Antonio, Texas 78229, United States
Fairfax, Virginia 22031, United States
Dummy, 99999, Germany